The Latest on Sotrovimab and Bebtelovimab COVID-19 Treatments

A new report from CNET provides the latest on available monoclonal antibody treatments. With Ba.2 or “stealth omicron” accounting for more than 70% of COVID cases in the U.S., it helps to have the latest information on these potentially life-saving treatments.

From CNET…

In March, GlaxoSmithKline said the FDA found that its treatment sotrovimab“unlikely” to be effective against the BA.2 variant. The companies added that they are preparing data on a higher dose of sotrovimab that may work against BA.2.

Sotrovimab, like other monoclonal antibodies, has been used as treatment for COVID-19 in people most at risk for severe COVID-19 disease or hospitalization in the early days of their symptoms.

Trending

HIT AND RUSSIAN: Russian Colonel Dies After His Own Troops Intentionally Run Him Over

Bebtelovimab, made by Eli Lilly, is a monoclonal antibody still authorized for use in patients 12 and up who have mild or moderate COVID-19 and are at high risk for severe disease. The antibody should be used when other treatments for high-risk patients are either unavailable or inappropriate, and given within the first seven days of COVID-19 symptoms, the FDA said. 

According to the FDA, “Bebtelovimab is not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. Treatment with bebtelovimab has not been studied in patients hospitalized due to COVID-19.”